Method for treating breast cancer

Patent metadata

Field	Value
Publication number	US-11857639-B2
Application number	US-202318450842-A
Country	US
Kind code	B2
Filing date	Aug 16, 2023
Priority date	Jun 18, 2021
Publication date	Jan 2, 2024
Grant date	Jan 2, 2024

Abstract

A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

First claim

The invention claimed is:

1. A method for treating a breast cancer in a subject in need of therapy, comprising:
administering to the subject a pharmaceutical composition comprising a nanomedicinal composition,
wherein the nanomedicinal composition comprises:
a nanocarrier comprising:
mesosilicalite; and
particles of a magnetic ferrite of formula MFe 2 O 4 disposed in the pores of the mesosilicalite, where M is Cu; and

a pharmaceutical agent mixture comprising cisplatin and curcumin disposed in the pores and/or on a surface of the nanocarrier;
wherein the nanocarrier has a BET surface area of 70 m 2 /g and an average pore volume of 0.1 cm 3 /u,
wherein the nanomedicinal composition releases 88% of the cisplatin and 40-50% of the curcumin over 72 hours in a solution with a pH of 5.6.

2. The method of claim 1 , wherein the mesosilicalite is in the form of particles having a mean particle size of 25 to 500 nm.

3. The method of claim 1 , wherein the magnetic ferrite is present in the nonmedicinal composition an amount of 15 to 45 wt % based on a total weight of the nanocarrier.

4. The method of claim 1 , wherein the magnetic ferrite has a mean particle size of 5 to 50 nm.

5. The method of claim 1 , wherein the pharmaceutical agent mixture further comprises at least one selected from the group consisting of carboplatin and oxaliplatin.

6. The method of claim 1 , wherein the pharmaceutical agent further comprises tamoxifen.

7. The method of claim 1 , wherein the nanomedicinal composition further comprises at least one selected from the group consisting of quercetin, rutin, coenzyme Q10, and gallic acid.

8. The method of claim 1 , wherein a weight ratio of the curcumin to the cisplatin is 1:1 to 10:1 in the nonmedicinal composition.

9. The method of claim 1 , wherein the pharmaceutical agent mixture is present in the nanomedicinal composition in an amount of 5 to 50 wt %, based on a total weight of nanomedicinal composition.

10. The method of claim 1 , further comprising exposing the subject to an alternating magnetic field after the administering, thereby raising the temperature of the nanomedicinal composition.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Almohazey Dana

Classifications

• A61K47/6923 Primary

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• A61K31/138

  Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

• A61K31/282 Primary

  Platinum compounds · CPC title

• A61K33/243

  Platinum; Compounds thereof · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title